CEL-SCI Corporation (NYSE American: CVM) has closed its best-efforts public offering of 6 million shares of common stock at $1.20 per share, generating gross proceeds of approximately $7.2 million before fees and expenses. The company announced that net proceeds will be used to support continued development of its lead investigational immunotherapy, Multikine, as well as for general corporate purposes and working capital.
Multikine (Leukocyte Interleukin, Injection) is designed to boost a patient's immune system before surgery, radiotherapy, and chemotherapy have damaged it, aiming to provide the greatest possible impact on survival. The therapy is intended to help the immune system target the tumor at a time when the immune system is still relatively intact, thought to be better able to mount an attack on the tumor. Multikine has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck.
The successful closing of this offering provides CEL-SCI with additional capital to advance its clinical programs and regulatory efforts. The company has operations in Vienna, Virginia, and near Baltimore, Maryland. For more information, visit the company's website at https://cel-sci.com/.
This financial milestone comes as CEL-SCI continues to pursue the development of Multikine, which represents a novel approach in cancer immunotherapy. The company's focus on neoadjuvant therapy—treatment given before primary therapy—could potentially improve outcomes for head and neck cancer patients. The funds from this offering are expected to support key activities, including ongoing clinical trials and preparations for potential regulatory submissions.
Investors and industry observers will be watching CEL-SCI's progress closely, as the company navigates the complex path to bringing Multikine to market. The additional capital provides a financial cushion to continue operations and advance its pipeline. The full press release can be accessed at https://ibn.fm/T5Ng2.
While the offering strengthens CEL-SCI's near-term financial position, the company still faces significant challenges, including clinical trial risks and the need for further funding. However, the closure of this offering marks a step forward in the company's mission to develop an innovative therapy for head and neck cancer patients.
